NCT03722550已完成不适用
Growth, Safety and Efficacy of a Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides: a Double-blind, Randomized, Controlled Trial
Société des Produits Nestlé (SPN)68 个研究点 分布在 3 个国家目标入组 789 人开始时间: 2018年9月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 789
- 试验地点
- 68
- 主要终点
- To compare recurrent incidences of illness of infants between the groups
研究概览
简要总结
The aim of this trial is to show that infants fed these new formulas, containing a blend of 5 Human Milk Oligosaccharides (HMOs), allow for growth in line with infants fed formulas without HMOs.
There will be different groups in the trial: three formula-fed groups and a breastfed group.
详细描述
These 5 HMOs are identical to the ones found naturally in human milk. They are natural prebiotics (or complex sugars) with potential health benefits. Prebiotics are natural compounds that help the establishment of beneficial gut bacteria (such as bifidobacteria), while preventing bad bacteria from doing harm. Supplementing diets with certain prebiotics has been shown to be well tolerated in adults and infants and to provide potential benefits.Therefore, the trial also aims to understand if consuming HMOs supplemented formulas could strengthen immunity and prevent common illnesses (for example, respiratory illnesses) in infants and toddlers. Furthermore, stool frequency and consistency will be monitored, so as to evaluate digestive tolerance to the formula.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Unique coding of the study products
入排标准
- 年龄范围
- 7 Days 至 21 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Evidence of personally signed and dated informed consent document indicating that the infant's parent(s)/Legally Acceptable Representative has been informed of all pertinent aspects of the study.
- •Infants whose parent(s)/Legally Acceptable Representative have reached the legal age of majority in the countries where the study is conducted.
- •Infants whose parent(s)/Legally Acceptable Representative are willing and able to comply with scheduled visits, and the requirements of the study protocol.
- •Infants whose parent(s)/Legally Acceptable Representative are able to be contacted directly by telephone throughout the study.
- •Infants whose parent(s)/Legally Acceptable Representative have a working freezer.
- •Infants must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •Healthy term (37-42 weeks of gestation) infant at birth.
- •At enrollment visit, post-natal age ≥ 7 days and ≤ 21 days (date of birth = day 0, 0.25 - 0.75 months old).
- •At enrollment, birth weight ≥ 2500g and ≤ 4500g.
- •For formula-fed group, infants must be exclusively consuming and tolerating a cow's milk infant formula at time of enrollment and their parent(s)/Legally Acceptable Representative must have independently elected, before enrollment, not to breastfeed.
- •For breastfed group, infants must have been exclusively consuming breast milk since birth, and their parent(s)/Legally Acceptable Representative must have made the decision to continue exclusively breastfeeding until at least 4 month of age.
排除标准
- •Infants with conditions requiring infant feedings other than those specified in the protocol.
- •Infants receiving complementary foods or liquids defined as 4 or more teaspoons per day or approximately 20 g per day of complementary foods or liquids at or prior to enrollment.
- •Infants who have a medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:
- •Evidence of major congenital malformations (e.g., cleft palate, extremity malformation).
- •Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis).
- •History of admission to the Neonatal Intensive Care Unit (NICU), with the exception of admission for jaundice phototherapy.
- •Other severe medical or laboratory abnormality (acute or chronic) which, in the judgment of the investigator, would make the infant inappropriate for entry into the study.
- •Infants who are presently receiving or have received prior to enrollment any of the following: medication(s) or supplement(s) which are known or suspected to affect the following: fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes); stool characteristics (e.g., glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose); growth (e.g. insulin or growth hormone); gastric acid secretion; or any study outcomes.
- •Currently participating or having participated in another clinical trial since birth
结局指标
主要结局
To compare recurrent incidences of illness of infants between the groups
时间窗: From Study Day 1 to 15 months of age
To compare recurrent incidences of illness (specifically lower and upper respiratory tract illnesses including bronchitis/bronchiolitis), of infants randomized to Test Groups (TG1 or TG2) versus Control Group (CG)
To compare the growth of infants between the groups
时间窗: From Study Day 1 to 4 months of age
To compare the growth (weight gain, g/day) of infants randomized to Test Groups (TG1 or TG2) versus Control Group (CG)
次要结局
- Absenteeism: Time away from daycare (infant) or work (parent)(From enrollment until 15 months of age)
- Blood Markers of immune health(At 6 months of age)
- Gastrointestinal tolerance(Stool sample collected at infant age less than 0.75, 3, 6, 12, and 15 months of age (a subset of 105 infants per formula group; 90 breastfed infants))
- Anthropometric measurements: Weight(From enrollment until 15 months of age)
- Anthropometric measurements: Length(From enrollment until 15 months of age)
- Anthropometric measurements: Head circumference(From enrollment until 15 months of age)
- Breastmilk collection for Human Milk Oligosaccharides profile analysis (breastfeeding mothers only)(At Study Day 90 +/- 5 days)
- Anthropometric measurements: World Health Organization (WHO) growth standard calculated z-scores(From enrollment until 15 months of age)
- Standard adverse events (AEs) reporting for safety assessment(From the time the informed consent form has been signed at enrollment infant age less than 21 days or 0.75 months through the 2 weeks post-study telephone contact at infant age 464 days)
- Vital signs: Body temperature(From enrollment until 15 months of age)
- Bone index measurement(From enrollment until 15 months of age)
- Infant illness and infection outcomes(at different stages of feeding 1st age Infant Formula, 2nd age Follow-up Formula, and 3rd age Growing-up Milk when applicable)
- Fecal microbiome composition, diversity, community type(Stool sample collected at infant age less than 0.75, 3, 6, 12, and 15 months of age (a subset of 105 infants per formula group; 90 breastfed infants))
- Fecal metabolic profile(Stool sample collected at infant age less than 0.75, 3, 6, 12, and 15 months of age (a subset of 105 infants per formula group; 90 breastfed infants))
- Cognitive and behavioral outcomes(At 15 months of age)
- Anthropometric measurements: BMI(From enrollment until 15 months of age)
- Vital signs: Heart rate(From enrollment until 15 months of age)
- Dietary pattern(From 6 months of age until 15 months of age)
- Medication use (specifically antimicrobials and antipyretics)(From enrollment until 15 months of age)
- Markers of immune and gut health(Stool sample collected at infant age less than 0.75, 3, 6, 12, and 15 months of age (a subset of 105 infants per formula group; 90 breastfed infants))
- DNA Genotyping of fucosyltransferase 2 and 3 (secretor status)(At Study Day 60 +/- 5 days)
- Vital signs: Infant respiration(From enrollment until 15 months of age)
研究者
研究点 (68)
Loading locations...
相似试验
已完成
不适用
Clinical Safety of a New Infant Starter Formula Containing 2 Human Milk Oligosaccharides (HMOs)HealthyNCT01715246Société des Produits Nestlé (SPN)176
已完成
不适用
Evaluation of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term InfantsInfantsNewbornNCT04218929ByHeart311
已完成
不适用
Efficacy and Safety of an Infant Formula With Milkfat and PrebioticsInfectionsStool FloraStool BiochemistryFood IntoleranceConstipationNCT01603719Waldkrankenhaus Protestant Hospital, Spandau128
Unknown
不适用
New Infant Formula Supports Adequate Growth in Healthy InfantsInfant DevelopmentNCT03614468Worthy Health80
已完成
不适用
Growth of Infants Fed New Starter FormulaDietary InterventionNCT01079208Société des Produits Nestlé (SPN)297